RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Laboratorios Farmaceuticos ROVI Stock

Laboratorios Farmaceuticos ROVI Stocks 2024

Laboratorios Farmaceuticos ROVI Stocks

53.19 M

Ticker

ROVI.MC

ISIN

ES0157261019

WKN

A0M0GQ

In 2024, Laboratorios Farmaceuticos ROVI had 53.19 M outstanding stocks, a 0% change from the 53.19 M stocks in the previous year.

The Laboratorios Farmaceuticos ROVI Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
2028e53.19
2027e53.19
2026e53.19
2025e53.19
2024e53.19
202353.19
202253.47
202155.4
202055.39
201955.18
201851.22
201749.26
201649.03
201549.54
201449.89
201349.8
201249.7
201149.7
201049.7
200949.6
200849.9
200750
200650
200550
200450

Laboratorios Farmaceuticos ROVI shares outstanding

The number of shares was Laboratorios Farmaceuticos ROVI in 2023 — This indicates how many shares 53.192 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Laboratorios Farmaceuticos ROVI earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Laboratorios Farmaceuticos ROVI's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Laboratorios Farmaceuticos ROVI’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Laboratorios Farmaceuticos ROVI's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Laboratorios Farmaceuticos ROVI Aktienanalyse

What does Laboratorios Farmaceuticos ROVI do?

Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Laboratorios Farmaceuticos ROVI's Shares Outstanding

Laboratorios Farmaceuticos ROVI's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Laboratorios Farmaceuticos ROVI’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Laboratorios Farmaceuticos ROVI’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Laboratorios Farmaceuticos ROVI’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

How many stocks are there of Laboratorios Farmaceuticos ROVI?

The current number of stocks of Laboratorios Farmaceuticos ROVI is 53.19 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Laboratorios Farmaceuticos ROVI are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Laboratorios Farmaceuticos ROVI evolved in recent years?

The number of shares of Laboratorios Farmaceuticos ROVI has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Laboratorios Farmaceuticos ROVI as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Laboratorios Farmaceuticos ROVI?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Laboratorios Farmaceuticos ROVI pay?

Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 1.74 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.

What is the dividend yield of Laboratorios Farmaceuticos ROVI?

The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.74 %.

When does Laboratorios Farmaceuticos ROVI pay dividends?

Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Laboratorios Farmaceuticos ROVI?

Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.

What is the dividend of Laboratorios Farmaceuticos ROVI?

For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.27 %.

In which sector is Laboratorios Farmaceuticos ROVI located?

Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorios Farmaceuticos ROVI kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Laboratorios Farmaceuticos ROVI pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Laboratorios Farmaceuticos ROVI in the year 2023?

In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.

In which currency does Laboratorios Farmaceuticos ROVI pay out the dividend?

The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Laboratorios Farmaceuticos ROVI

Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.